Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection

A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraaij, P. L. A., van der Vries, E., Beersma, M. F. C., Riezebos-Brilman, A., Niesters, H. G. M., van der Eijk, A. A., de Jong, M. D., Reis Miranda, D., Horrevorts, A. M., Ridwan, B. U., Wolfhagen, M. J. H. M., Houmes, R. J., van Dissel, J. T., Fouchier, R. A. M., Kroes, A. C. M., Koopmans, M. P., Osterhaus, A. D. M. E., Boucher, C. A. B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156108/
https://www.ncbi.nlm.nih.gov/pubmed/21844304
http://dx.doi.org/10.1093/infdis/jir397
_version_ 1782210175454674944
author Fraaij, P. L. A.
van der Vries, E.
Beersma, M. F. C.
Riezebos-Brilman, A.
Niesters, H. G. M.
van der Eijk, A. A.
de Jong, M. D.
Reis Miranda, D.
Horrevorts, A. M.
Ridwan, B. U.
Wolfhagen, M. J. H. M.
Houmes, R. J.
van Dissel, J. T.
Fouchier, R. A. M.
Kroes, A. C. M.
Koopmans, M. P.
Osterhaus, A. D. M. E.
Boucher, C. A. B
author_facet Fraaij, P. L. A.
van der Vries, E.
Beersma, M. F. C.
Riezebos-Brilman, A.
Niesters, H. G. M.
van der Eijk, A. A.
de Jong, M. D.
Reis Miranda, D.
Horrevorts, A. M.
Ridwan, B. U.
Wolfhagen, M. J. H. M.
Houmes, R. J.
van Dissel, J. T.
Fouchier, R. A. M.
Kroes, A. C. M.
Koopmans, M. P.
Osterhaus, A. D. M. E.
Boucher, C. A. B
author_sort Fraaij, P. L. A.
collection PubMed
description A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4–11 days) compared with 14 days (range, 6–21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.
format Online
Article
Text
id pubmed-3156108
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-31561082011-09-01 Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection Fraaij, P. L. A. van der Vries, E. Beersma, M. F. C. Riezebos-Brilman, A. Niesters, H. G. M. van der Eijk, A. A. de Jong, M. D. Reis Miranda, D. Horrevorts, A. M. Ridwan, B. U. Wolfhagen, M. J. H. M. Houmes, R. J. van Dissel, J. T. Fouchier, R. A. M. Kroes, A. C. M. Koopmans, M. P. Osterhaus, A. D. M. E. Boucher, C. A. B J Infect Dis Major Articles and Brief Reports A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4–11 days) compared with 14 days (range, 6–21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated. Oxford University Press 2011-09-01 /pmc/articles/PMC3156108/ /pubmed/21844304 http://dx.doi.org/10.1093/infdis/jir397 Text en © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Major Articles and Brief Reports
Fraaij, P. L. A.
van der Vries, E.
Beersma, M. F. C.
Riezebos-Brilman, A.
Niesters, H. G. M.
van der Eijk, A. A.
de Jong, M. D.
Reis Miranda, D.
Horrevorts, A. M.
Ridwan, B. U.
Wolfhagen, M. J. H. M.
Houmes, R. J.
van Dissel, J. T.
Fouchier, R. A. M.
Kroes, A. C. M.
Koopmans, M. P.
Osterhaus, A. D. M. E.
Boucher, C. A. B
Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
title Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
title_full Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
title_fullStr Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
title_full_unstemmed Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
title_short Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
title_sort evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza a (h1n1) infection
topic Major Articles and Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156108/
https://www.ncbi.nlm.nih.gov/pubmed/21844304
http://dx.doi.org/10.1093/infdis/jir397
work_keys_str_mv AT fraaijpla evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT vandervriese evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT beersmamfc evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT riezebosbrilmana evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT niestershgm evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT vandereijkaa evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT dejongmd evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT reismirandad evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT horrevortsam evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT ridwanbu evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT wolfhagenmjhm evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT houmesrj evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT vandisseljt evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT fouchierram evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT kroesacm evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT koopmansmp evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT osterhausadme evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection
AT bouchercab evaluationoftheantiviralresponsetozanamiviradministeredintravenouslyfortreatmentofcriticallyillpatientswithpandemicinfluenzaah1n1infection

Ejemplares similares